# PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of HCC

> **NCT04273100** · PHASE2 · UNKNOWN · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 56 (estimated)

## Conditions studied

- Hepatocellular Carcinoma Non-resectable

## Interventions

- **COMBINATION_PRODUCT:** PD-1 mAb combined with TACE and lenvatinib

## Key facts

- **NCT ID:** NCT04273100
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-11-14
- **Primary completion:** 2020-12-31
- **Final completion:** 2021-06-30
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2020-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04273100

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04273100, "PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of HCC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04273100. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*